Author

Audrey Meade

Fred and Pamela Buffett Cancer CenterORCID 0009-0001-2503-2354Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:spatial domain detection· 1 Approach:statistical model· 1

Frequent Co-Authors

Amelia CephasiD· 1 shared Christopher P. TarantoiD· 1 shared Jennifer M. BaileyiD· 1 shared Katherine E. AnkenbaueriD· 1 shared Kathleen E. DelGiornoiD· 1 shared Kelsey A. KluteiD· 1 shared Khadija Shahab TurabiiD· 1 shared Marina Pasca di MaglianoiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amelia CephasORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintOct 25, 2026

Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer

Khadija Shahab Turabi, Urvinder Kaur Sardarni, Katherine E. Ankenbauer…·Jennifer M. Bailey

This study shows that combining CD73 and RAS(ON) inhibition reduces tumor growth and immune suppression in pancreatic cancer by targeting KRAS-MAPK driven CD73 signaling.

DOI 10.64898/2026.10.20.760559

mousebulk RNA-seq

𝕏 PostBluesky